Too much nonsense as usual so I want to cut my post to the bone talking purely about buying, holding or selling nwbo for profit.
The status: today is more than 4 months after DL pr
For most small biotech companies they would have already pr tld, and yet we have not seen the tld pr yet because the company suggested they would announce tld and a publication in a closed by fashion.
A publication of detail data analysis according to Highwayman's link takes a year in average. However, NWBIO is not any way of that average company, and there are also examples of companies which take only a couple or a few months after DL for a publication for detail analysis.
For NWBIO
1) it's suggested NWBIO would release tld and publication almost simultaneously, unlike any average company which usually releases tld within two months of its DL pr, which takes the pressure off from publication (NWBIO is pressured for a quick publication from various fronts without announcing tld as soon as possible from DL pr);
2) NWBIO needs to raise funds for operations, and it cannot do that a) withholding tld/knowledge of trial results; and b) because it has run out of authorized shares.
As a result, NWBIO must pr tld at least in the near future if publication is still far away due purely to its financial needs. As a matter of fact, since it's already four months after DL pr, it's highly likely the publication may be about ready on any day ahead. Besides, the annual shareholder meeting is fast approaching, if prior years' experiences is a guide, we may be receiving notice on any day within this month. It's highly unlikely NWBIO would not reveal tld on or before the shareholder meeting.
Bottomline, from all we have known, it's quite probable DCVax-l P3 trial for GBM is significant in meeting its primary endpoint, and it's also quite probable it also meets some of its secondary endpoints. If DCVax-l is approved, it's very practical NWBIO would quickly achieve dominant market success/shares. A share price of $10 is readily achievable shortly after successful tld pr...
Conclusion:
No matter how patient you are or will be, the trial is most probably successful in meeting its major endpoints for nGBM, and it's an educated/studied speculation NWBIO may also seek approval of rGBM, which may explain at least in part for the existing long quiet period.
I don't know about you. Definitely as I have said several times in the past few months, I am a buyer, ie, net net my shares have steadily increased, bringing my average price steadily up.
